Clinical Trial Update: SBRT + TACE for Primary Hepatocellular Carcinoma [NA]

View source ↗

Summary

This clinical trial update indicates that the study evaluating the combination of SBRT and TACE for hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: University of Pittsburgh | Conditions: Hepatocellular Carcinoma | NA | Status: WITHDRAWN